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Evolving from the well-established GMP 48L Nunc™ Cell Factory™ 
(CF) process, AGC Biologics has developed a robust, scalable, high 
quality and quantity process for the industrial-scale production of 
lentiviral (LV) vectors for use in gene-modified cell therapy or in 
vivo gene therapy. This platform includes vector production in the 
iCELLis® bioreactor, downstream purification and concentration 
by chromatography and tangential flow filtration (TFF) steps and 
sterile filtration and filling in different formats. Upstream process was 
developed leveraging the scale down iCELLis® Nano system where key 
process parameters were screened in order to increase productivity, 
producing a bulk vector with consistently low contaminant profile. Data 
obtained on full-scale iCELLis® 500 system confirmed full scalability 






































The downstream process was designed to remove main process related 
contaminants (Host Cell Proteins, Host Cell DNA, plasmid DNA and 
BSA), thus maintaining vector infectivity. The process consists of an 
anion exchange chromatography step that captures and concentrates 
the vector, enabling 80% recovery while removing HCPs, DNA and 
BSA. Eluted vector is then concentrated and diafiltered with TFF 
using hollow fibers. With this step, the vector is further concentrated 
with 80% recovery, and additional contaminant removal is achieved. 
The vector is then 0.2µ sterile filtrated and filled in vials. Total process 









































Final purified vector data shows a similar impurity profile as the 
established 48L CF’s process. The system has already been successfully 
implemented for the manufacture for different vectors with different 
Gene of Interest (GoI). With the ability to produce a volume of 4x 
without a loss in quality, the iCELLis® 500 platform offers a scalable 
and cost-effective solution with regards to the number of patients 
treated versus the cost of production and quality control. Moreover, 
the possibility to leverage the analytical platform already in use for 
the GMP 48L CF’s process accelerates transition from development to 
GMP clinical and commercial production with reduced comparability 
exercises.
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Intensification of cell-based production processes is key to improving 
oncolytic vaccine logistics and economics by saving on GMP space, 
time, labor, and feedstock. Many promising vectors, including 
those based on vaccinia virus (e.g. CF33, JX-594/Pexa-Vec) are 
still produced using flask-based culture due to the cost, effort, and 
uncertainty involved in adapting to stirred-tank or perfusion processes. 
Based on prior success culturing adherent cells (e.g. HEK293, 
A549, CV-1) to high densities (107-8 cells/mL) using the scalable 
high-density cell respirator (HDCR) bioreactor, we hypothesized 
that the platform could support orders-of-magnitude-intensified 
production of replication competent viruses. Here we report on CF33 
virus production as a proof-of-concept for oncolytic virotherapy. 
Bioreactor cartridges were produced based on a 4-stack of 600 cm2 
HDCR membranes, featuring a proprietary gas perfusable and 
permeable microarchitecture that optimally oxygenates cells even 
at high densities. Media perfusion was feedback-controlled based 
on glucose measurements in the waste stream. A549 cells were 
seeded into the bioreactor on microcarriers, expanded 10-fold to 
mid-107 cells/mL densities, infected with CF33 virus (MOI of 0.1), 
and harvested 48 hours post-infection. CF33 virus was gradient 
purified and titered for functional virus by plaque forming assay. 
Multiple production runs using different strains of CF33 virus 
validated the reproducibility of the process, as summarized in Table 
1. Importantly, cell specific titers (PFU/cell) remained comparable 
to conventional flask-based production, leading to significant 
intensification due to the higher cell densities supported in the HDCR 
bioreactor. Volumetric productivity is on the order of 100× that of cell 
factories. The efficient usage of media due to the gas-media decoupled 
operation of the HDCR bioreactor enables gradient-purified virus costs 
of around $500/1010 PFU. This is significantly below the $10,000/1010 
PFU charged by CMOs and supports our mission of democratizing 
access to life saving medicines. The straightforward adaptation of 
CF33 virus production from a flask-based to a high yield, intensified 
process highlights the logistical and economical advantage of the 
HDCR platform for oncolytics.
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6E10 28 10.5 402
CF33-
mCD19t 2.6E11 130 10.9 275
CF33-tk 2.8E10 18 10.6 540
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Endotoxin, otherwise known as lipopolysaccharide (LPS), is the 
major component of the outer membrane of Gram-negative bacteria. 
Endotoxin can be released by bacteria and co-purify with AAV 
therapeutics. In vivo, endotoxin can cause sepsis that leads to excessive 
inflammation, leading to multiple organ failure and potentially death. 
As such, endotoxin must be monitored as an adventitious agent that can 
adversely affect the safety and efficacy of AAV drug products. Preclinical 
research animal model endotoxin limits based on the threshold of 5 
EU/kg for human doses are calculated to be approximately 1.5 EU/mL. 
We have investigated three endotoxin removal strategies to clear AAV 
vectors of endotoxin for potential use in mouse and primate studies. 
AAV viral preps with titers of 1 e13 GC/mL and 6 e12 GC/mL were 
spiked up to 980 EU/mL with LPS. A commercial endotoxin removal 
kit was compared to published endotoxin removal protocols based on 
detergents Triton X-100 and Triton X-114. The commercial product 
reduced endotoxin content by 30-fold but sacrificed 30 % of the titer. 
Triton X-100 reduced endotoxin by 3,500-fold but sacrificed 60% of 
the titer. Triton X-114 was the most efficient at removing LPS, up to 
60,000-fold for final levels less than 0.100 EU/mL, while maintaining 
the highest titer recovery of 75%. Endotoxin removal using Triton 
X-114 is recommended for quick processing of LPS-contaminated 
AAV therapeutics.
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Transient transfection is presently the primary approach widely used 
for recombinant adeno-associated virus (rAAV) production. In this 
study, we have explored the critical process parameters for rAAV 
production. We have evaluated multiple polyethylenimine (PEI)-based 
transfection reagents and identified PEIpro® as the lead candidate. 
We have also compared various cell culture media formulations and 
observed high compatibility of PEIpro® with different media types. Key 
transfection parameters, including transfection cell densities, plasmid 
DNA amounts, transfection complex volume, transfection/ harvest 
timings as well as bioreactor settings were also screened through 
DoE studies to optimize the manufacturing process. The optimized 
production process shows high robustness and improved batch-to-
batch consistency and reproducibility.
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Receptor-targeted lentivirus vectors (LV) are emerging as a key 
technology for selective gene delivery to key target cell populations 
both during ex vivo and in vivo transduction protocols. Currently, the 
best developed approach is to pseudotype the LV with paramyxovirus 
Fusion (F) and Hemagglutinin (H) glycoproteins whose natural 
tropisms are ablated and whose attachment specificity is redirected 
via cell specific polypeptide binding domains (eg. scFv) displayed on 
the C-terminus of the H protein. LV pseudotyped with engineered 
measles F and H glycoproteins can be efficiently retargeted but 
pre-existing anti-measles antibodies render them ineffective for in 
vivo gene delivery. An addittional limitation of current pseudotying 
strategies with receptor-targeted paramyxovirus glycoproteins is 
the requirement for extensive engineering of their cytoplasmic tail 
regions to allow for incorporation into lentiviral particles. Here we 
show that fusion-competent, full-length canine distemper virus 
(CDV) glycoproteins (ie without engineered cytoplasmic tails) can 
be efficiently pseudotyped onto LVs. Cytoplasmic-tail truncations 
of the CDV envelope glycoproteins did not improve efficiency of 
pseudotyping, while swapping the cytoplasmic tail of CDV-H with 
the heterologous tail from the measles virus H protein completely 
abolished it. To generate an EpCAM-targeted lentiviral vector, we 
engineered CDV glycoproteins to ablate their tropisms for cognate 
receptors, canine SLAMF1 and human/canine nectin4, and fused a 
designed ankyring repeat proteins (DARPin) specific for EpCAM to 
the C-terminus of the CDV-H protein. The receptor-targeted CDV-
LVs showed improved EpCAM-specific transduction efficiency when 
compared with their MeV-based counterparts. Our current effort 
focus on the generalizability to other receptors of choice. Lentiviral 
vectors pseudotyped with full-length retargeted CDV glycoproteins 
might provide a valuable addition to the family of targeted LVs for 
gene therapy purposes.
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Adeno-Associated Viruses (AAVs) are a well-established vector 
for gene therapy applications due to their ease of use and low 
pathogenicity. However, their production yields empty particles, 
that lack the genetic material required for the therapy, at ratios up 
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